Bioelectronics Corp (OTCMKTS:BIEL) has set the OTC Markets on fire after receiving U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain. With the stock trading at just $.0011 and a 52-week high of only $.0017, there’s a lot more runway for this one to climb. As we taking a deeper look at OTCMKTS:BIEL, there’s a lot we like.
First up, here’s a little background info for anyone not familiar with OTCMKTS:BIEL. This company is a healthcare entity based out of Maryland, which bills itself as a developer and marketer of disposable, drug-free, pain therapy, and wearable medical devices. It’s got a pretty robust product portfolio (this is before the latest approval, which we’ll get to shortly), which includes a menstrual pain product, a heel pain insole, and a wound closing and pain treatment. Its products are marketed under the names ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy.
The latest news is that OTCMKTS:BIEL received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new, over-the-counter marketing clearance was granted for the drug-free ActiPatch® medical device, for the indication: “adjunctive treatment of musculoskeletal pain.” The ActiPatch was already FDA-cleared for over-the-counter treatment of pain from knee osteoarthritis and plantar fasciitis (heel pain) in 2017. The latest clearance expands these indications to cover all musculoskeletal pain complaints. Kelly Whelan, President of BioElectronics, stated:
“The Company intends to capitalize on this new clearance by offering additional products to retail channel partners, in alignment with our 2020 strategy to prioritize the OEM (Original Equipment Manufacturer) aspects of our business.” With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.”
This news follows up the publication of a study last October in the journal Pain Research and Management, titled “A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy”. The study demonstrated that users who experience pain relief after using ActiPatch® for 7 days, continued to experience this relief over at least 6 months when ActiPatch® use is continued.
The Study Key Points found:
- 240 Subjects were recruited into 6-month study of 7-day trial users of the ActiPatch medical device to treat chronic pain.
- 7 days after initial treatment, average pain was reduced by 65%, from 8.2 to 2.9 on a 0-10 visual analog scale (VAS).
- At the 6-month measurement, the average VAS was 3.3, indicating a 60% pain reduction from baseline.
- Sustained pain relief translated into improved quality of life and reduced medication use for the majority of the subjects.
Currently trading with a market cap of just $25 million, OTCMKTS:BIEL is an exciting story among microcaps. With the stock currently trading at just $.0011, there’s a lot more upside than downside. For microcap investors looking for a discount entry opportunity, OTCMKTS:BIEL fits the bill.
We will be updating our subscribers as soon as we know more. For the latest updates on BIEL, sign up below!
Disclosure: We have no position in BIEL and have not been compensated for this article.